Targeting a $5B brand, Samsung and Merck launch Remicade biosim at 35% discount
admin 24th July 2017 Uncategorised 0After the first biosimilar of Johnson & Johnson’s big-selling immunology drug Remicade hit the market last year at a modest discount, another has come along with an even deeper cut.
More: Targeting a B brand, Samsung and Merck launch Remicade biosim at 35% discount
Source: fierce